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AbstrAct:
Vosaroxin (formerly voreloxin) is a first-in-class anticancer quinolone derivative 
that intercalates DNA and inhibits topoisomerase II, inducing site-selective 
double-strand breaks (DSB), G2 arrest and apoptosis. Objective responses and 
complete remissions were observed in phase 2 studies of vosaroxin in patients 
with solid and hematologic malignancies, and responses were seen in patients 
whose cancers were resistant to anthracyclines. The quinolone-based scaffold 
differentiates vosaroxin from the anthracyclines and anthracenediones, broadly 
used DNA intercalating topoisomerase II poisons. Here we report that vosaroxin 
induces a cell cycle specific pattern of DNA damage and repair that is distinct from 
the anthracycline, doxorubicin. Both drugs stall replication and preferentially 
induce DNA damage in replicating cells, with damage in G2 / M > S >> G1. 
However, detectable replication fork collapse, as evidenced by DNA fragmentation 
and long tract recombination during S phase, is induced only by doxorubicin. 
Furthermore, vosaroxin induces less overall DNA fragmentation. Homologous 
recombination repair (HRR) is critical for recovery from DNA damage induced 
by both agents, identifying the potential to clinically exploit synthetic lethality.
INtrODUctION
Quinolone derivatives have recently been described 
as an alternative scaffold to the classic antineoplastic 
topoisomerase II poisons, including the anthracyclines, 
anthracenediones and epipodophyllotoxins [1-5]. These 
drugs are broadly used in the treatment of both solid and 
hematologic malignancies [6-8]. Objective responses and 
complete remissions in phase 2 studies of acute myeloid 
leukemia and platinum-resistant ovarian cancer were 
observed with vosaroxin (formerly voreloxin), a first-
in-class anticancer quinolone derivative [9-11]. In both 
settings, responses were seen in patients whose cancers 
were resistant to anthracyclines. Vosaroxin is a DNA 
intercalating topoisomerase II poison [1], a feature it 
shares with the anthracyclines and anthracenediones. In 
contrast the epipodophyllotoxins do not intercalate DNA 
and directly interact with topoisomerase II. 
Topoisomerase II exists in two isoforms, α 
and β, of which topoisomerase IIα has been studied 
most extensively. The enzyme is essential for the 
maintenance of DNA topology, disentangling DNA 
following replication, and is required to maintain 
correct chromosome condensation, decondensation, and 
segregation [12-14]. Expression of topoisomerase IIα 
is highest in mitotic cells and peaks at G2 / M phase of 
the cell cycle [12, 15, 16]. Hallmarks of topoisomerase 
II poisoning are the induction of DNA double-strand 
breaks (DSB) and G2 arrest [17]. However, the nature of 
the drug / enzyme / DNA interaction drives the specifics 
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of DNA damage including sequence selectivity, location 
and extent of the induced DSBs, and the phase of the cell 
cycle in which they arise. Consequently the molecular 
characteristics of the drug-induced DNA damage and 
DNA damage response cannot be extrapolated directly 
from one molecular scaffold to another, based simply 
upon a common enzyme target. Thus the non-intercalating 
topoisomerase II poison etoposide causes extensive 
DNA laddering, while vosaroxin intercalates DNA and 
induces site-selective DNA DSB at G/C rich sequences 
[1], a characteristic of the quinolone core structure [18]. 
Further, although the anthracyclines are also DNA-
intercalating topoisomerase II poisons, they drive 
additional DNA damage through non-topoisomerase II 
mediated mechanisms, including the induction of reactive 
oxygen species (ROS) [19, 20]. The generation of ROS 
results in the formation of base mutations, anthracycline-
DNA adducts and cross-links [21-26], and is linked to 
the scaffold-based cardiomyopathy associated with the 
anthracyclines [20, 24, 27, 28]. These anthracycline-
induced processes are not dependent upon the levels of 
expression of topoisomerase II, and the relative roles of 
each of them in the clinical activity and toxicity of the 
compounds is not fully established [8, 20, 22]. In contrast 
vosaroxin generates minimal ROS and the generation of 
ROS or DNA alkylation are not associated with the core 
quinolone structure [1]. 
Identification of the processes that repair vosaroxin-
induced DNA DSB is critical for the further development 
of rational, clinically testable hypotheses that direct the 
selection of target indications and subpopulations. Two 
major pathways are active in the repair of DNA DSB; 
non-homologous end joining (NHEJ) and homologous 
recombination repair (HRR). The complexities of these 
pathways are reviewed by Wyman and Kanaar [29]. The 
phase of the cell cycle in which DNA damage is induced 
is critical in determining which of the response processes 
predominate. Because HRR requires a donor, homologous 
Figure 1: Vosaroxin- and doxorubicin -induced DNA Dsb are increased in replicating cells. The cell cycle dependence of 
vosaroxin-induced DNA damage was investigated using MO59K glioma cells which are large and highly adherent, and thus amenable to 
centrosome staining and analysis via immunofluorescence. Cells were treated for 6 hours with 1 or 9 µM vosaroxin (A) or 1 µM vosaroxin or 
0.1 µM doxorubicin (B). Average γH2AX fluorescence intensity is displayed, with each symbol representing one cell. Cell cycle phases were 
established by analysis of centrosome size and number, and representative images are shown in Figure S1. The number of cells counted per 
phase is shown (n). Mean intensity is represented by horizontal line on the graph and listed below with standard error of the mean (SEM). Data 
are representative of three (vosaroxin) and two (doxorubicin) independent experiments.
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DNA sequence to replace the damaged region, this process 
is prevalent in mitotic cells when a copy of the target DNA 
is available for exchange [30]. The characteristics of the 
DNA damage further subdivide the molecular nature of 
the HRR response [31, 32]. 
The focus of the current investigation was the analysis 
of the cell cycle phase specific toxicity of vosaroxin, and 
the identification of the DNA damage response processes 
that are critical to recovery from the associated toxic 
lesions. As a component of anthracycline toxicity is 
mediated through DNA intercalation and topoisomerase 
II poisoning, vosaroxin and doxorubicin were compared 
and contrasted in experiments that analyzed the extent and 
timing of DNA damage and cytotoxicity, and the DNA 
damage response mechanisms involved in repair of the 
damage. Understanding the processes that are essential for 
recovery from vosaroxin exposure will facilitate clinical 
exploitation of synthetic lethality. 
rEsULts
Vosaroxin-induced DNA damage is preferential 
for replicating cells
The cell-cycle dependence of vosaroxin-induced 
DNA damage was investigated using MO59K glioma 
cells. Cell cycle phases were defined by centrosome 
size and number into G1 (single small centrosome), 
late S / G2 (larger centrosome) and late G2 / M (2 
centrosomes) phases. Representative images are shown in 
Supplementary Figure 1. DNA damage was evaluated by 
staining for γH2AX and quantifying the stain intensity per 
nucleus, which is more diagnostic of DSB than overall 
γH2AX staining [33]. As shown in Figure 1, vosaroxin 
induced dose-dependent damage predominantly in the late 
G2 / M and late S / G2 populations. Vosaroxin at both 1 
Figure 2: Vosaroxin induces DNA fragmentation independent of DNA synthesis, in contrast with doxorubicin which 
induces s phase dependent and independent fragmentation. SPD8 cells were treated for 4 hr with 20 µM vosaroxin (V), 3 µM 
doxorubicin (DOX), 3 µM aphidicolin (Aph) or with vosaroxin or doxorubicin plus aphidicolin (+Aph) to arrest cells in S phase. Controls 
included 50 Gy of γ-irradiation (50 Gy) or DMSO only (Con). A) PFGE following 24 hr run. M = molecular markers. DNA fragment size 
is shown in Mbp. B) Luminescence intensity plots, in arbitrary units, showing data from vosaroxin treated cells +/- aphidicolin, doxorubicin 
treated cells +/- aphidicolin or an overlay of vosaroxin and doxorubicin treated cells with 50 Gy data included as positive control reference. 
A shift in the presence of aphidicolin indicates S phase dependent fragmentation. No difference was detected for vosaroxin + /- aphidicolin.
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and 9 µM induced significantly less damage in G1 than 
in late S / G2 / M. In comparison with an equitoxic dose 
of doxorubicin (0.1 µM), vosaroxin induced less overall 
DNA damage.
the vosaroxin-induced DNA fragmentation 
pattern differs from that of doxorubicin
We have previously reported that vosaroxin induces 
dose-dependent and site-selective DNA fragmentation [1]. 
In the present study, the dependence of fragmentation upon 
active DNA synthesis was investigated and compared with 
doxorubicin. To ensure detectable DNA fragmentation, 
relatively high doses of vosaroxin (20 µM) and doxorubicin 
(3 µM) were used, with or without aphidicolin to induce 
an S phase block. SPD8 cells were exposed to drug or 
vehicle control for 4 hrs, prior to fragmentation analysis 
by pulsed-field gel electrophoresis (PFGE). Vosaroxin-
induced DNA fragmentation appeared unaffected by 
aphidicolin (Figure 2). In contrast, doxorubicin induced 
a higher number of DNA fragments in the 1.6 – 0.2 Mbp 
range that were reduced in the presence of S phase block 
(Figure 2). A similar effect was previously reported for 
etoposide-induced DSBs [34].These data, combined with 
the DNA damage data shown in Figure 1, suggest that the 
vosaroxin-induced DNA fragmentation is distinct from 
that induced by doxorubicin and occurs during the G2 / M 
phases, while being undetectable during S phase. 
Vosaroxin and doxorubicin induce cytotoxicity 
both during and independent of s phase
To determine when in the cell cycle vosaroxin-
induced DSB are cytotoxic, SPD8 cells were exposed for 
4 hours to equitoxic doses of vosaroxin or doxorubicin 
with or without aphidicolin, followed by 7 day colony 
growth in drug-free media. Although S phase independent 
toxicity (colony growth inhibition remaining in the 
presence of S phase block) accounted for the majority of 
growth inhibition by both drugs (Figure 3), a component 
Figure 3: Vosaroxin and doxorubicin are cytotoxic both during and independent of DNA synthesis. SPD8 cells were exposed 
for 4 hr to 2 µM vosaroxin (V), 0.3 µM doxorubicin (DOX), 0.5 µM aphidicolin (Aph), or to vosaroxin or doxorubicin plus aphidicolin (+Aph) 
to arrest cells in S phase. Controls were treated with DMSO only (Con). Colony growth was evaluated after 7 days. Cloning efficiency is 
plotted as percent of untreated control. The graphic outlines the experimental approach, which is designed to identify S phase dependent and 
independent cytotoxicity. S phase independent toxicity (dotted bracket) is identified by the growth inhibition that occurred in the presence of S 
phase block. The S phase dependent toxicity (solid bracket) is determined by subtraction of S phase independent toxicity from overall toxicity. 
Both drugs demonstrate a component of S phase toxicity, however the majority of cytotoxicity is S phase independent. Data represent the mean 
of 3 independent experiments, error bars represent SEM. 
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of cytotoxicity was also S phase dependent. 
Vosaroxin-induced DNA damage is repaired by 
HRR processes that are cell cycle phase specific 
and are differentiated from doxorubicin
HRR has been shown previously to be involved in 
the repair of doxorubicin-induced DNA damage [23] and 
plays a major role in DNA DSB repair during S and G2 / M 
phases of the cell cycle (reviewed by Helleday et al [30]). 
To further elucidate vosaroxin’s molecular mechanism of 
action, and to identify cellular backgrounds which may 
be particularly sensitive to the drug, the contribution of 
HRR to the repair of vosaroxin-induced DNA damage 
was investigated and compared with doxorubicin. Both 
the activation of HRR and the implementation of long 
tract recombination were assessed. HRR activation was 
detected by analysis of RAD51 focus formation, which 
serves as an early HRR signal with broad substrate 
specificity [34]. As shown in Figure 4A, exposure for 4 
hr to either doxorubicin or vosaroxin triggered RAD51 
foci formation. The blockade of DNA synthesis reduced 
the number of foci to levels comparable with (vosaroxin) 
or below (doxorubicin) the level of aphidicolin control, 
indicating that the detected foci represent HRR triggered 
during active DNA synthesis. Consistent with these data 
is the dose-dependent S phase prolongation induced 
by vosaroxin (Supplementary Figure 2). In contrast, 
vosaroxin-induced long tract recombination, as detected 
by hprt reversion, was not detectably reduced by S 
phase block (Figure 4B), suggesting that HR-mediated 
reversion events occur principally if not exclusively at 
G2 / M. Contrasting with vosaroxin, doxorubicin-induced 
recombination events were modestly but significantly 
reduced by S phase block (p = 0.04), indicating that 
long tract recombination contributes to the repair of 
doxorubicin-induced DNA damage both during and 
independent of DNA synthesis. The moderate level of 
reversion events that were induced by both drugs is 
representative of topoisomerase II targeting agents [34]. 
Hrr compromised cells are sensitized to 
vosaroxin and doxorubicin
The CHO AA8 RAD51D mutant cell line (clone 
51D1) harbors a genetic knockout of RAD51D and shows 
increased sensitivity to DNA DSB-inducing agents, while 
the matched line (clone 51D1.3) is reconstituted for 
RAD51D expression [35]. These cell lines were used to 
examine the role of HRR in recovery from vosaroxin and 
doxorubicin-induced cytotoxicity. As shown in Figure 
5A, cells with a compromised HRR pathway were 22-
Figure 4: Vosaroxin and doxorubicin induce Hrr during and independent of DNA synthesis. A) Vosaroxin and doxorubicin 
trigger HRR during S phase. SPD8 cells were exposed for 4 hr to 2 µM vosaroxin (V), 0.3 µM doxorubicin (DOX), 0.5 µM aphidicolin (Aph), 
or with vosaroxin or doxorubicin plus aphidicolin (+Aph) to arrest cells in S phase. Controls were treated with DMSO only (C). The percent 
of cells with >9 RAD51 foci, representative of HRR activation, is plotted. The dashed horizontal line represents RAD51 foci induced by 
aphidicolin alone. Brackets represent the differential between vosaroxin or doxorubicin +/- aphidicolin (ie; vosaroxin alone minus vosaroxin 
+ Aph). A decrease in the presence of Aph for both drugs indicates S phase dependent induction of RAD 51 foci. Data represent the mean of 
3 independent experiments, error bars represent SEM. B) S phase block reduces doxorubicin-induced but not vosaroxin-induced long tract 
recombination . SPD8 cells were exposed for 4 hr to 2 µM vosaroxin (V), 0.3 µM doxorubicin (DOX), 0.5 µM aphidicolin (Aph), or with 
vosaroxin or doxorubicin plus aphidicolin (+Aph) to arrest cells in S phase. Controls were treated with DMSO only (C). The same population 
of treated cells were plated for cloning efficiency (Figure 3). Revertants / recombinants were selected by growth for 7 days in the presence of 
HAsT. The horizontal dashed line denotes reversion / recombination in the presence of aphicicolin control. To determine S phase dependent 
recombination events that are induced by each drug, the number of recombination events in the presence of drug + Aph are subtracted from 
the number of events with drug alone (ie; revertants with vosaroxin alone minus vosaroxin + Aph). No significant difference was detected for 
vosaroxin. A modest but significant difference was detected for doxorubicin (p=0.04). Data are plotted as revertants / 105 cells, and represent 
the mean of 3 independent experiments. Error bars represent SEM. 
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fold more sensitive to vosaroxin-induced inhibition of 
proliferation, and 12.5-fold more sensitive to doxorubicin. 
Further, as shown in Supplementary Figure 3, increased 
sensitivity to vosaroxin-induced G2 arrest was observed 
in the HRR compromised mutant background. Onset of 
arrest was observed at 0.004 µM as compared to 0.037 
µM (approximately 10-fold shift) in the HRR competent 
cell line.
To confirm that the enhanced sensitivity of HRR 
compromised cells is a function of reduced ability to repair 
vosaroxin- or doxorubicin- induced DNA damage, DNA 
repair was evaluated over time following 6 hr exposure to 
the compounds. Cells were treated with equitoxic doses of 
vosaroxin, doxorubicin or with DMSO control, followed 
by washout and quantification of RAD51 foci over 
time. As shown in Figure 5B, within 16 hr the number 
of detectable foci in vosaroxin- or doxorubicin-treated 
HRR competent cells was reduced to levels comparable 
with DMSO-treated controls, whereas HRR compromised 
cells sustained levels of foci that were significantly above 
background levels for the duration of the assay (40 hr). 
Thus the enhanced sensitivity to both vosaroxin or 
doxorubicin of HRR compromised cells correlates with 
an impaired ability to repair drug-induced DNA DSB. 
Figure 5: Hrr compromised cells are sensitized to vosaroxin and doxorubicin. A) Vosaroxin and doxorubicin are more cytotoxic 
for RAD51D null cells. The matched cell lines RAD51D1 (RAD51D null) and RAD51D1.3 (matched, RAD51D reconstituted) were exposed to 
a dose-titration of vosaroxin, doxorubicin or DMSO control for 72 hr. Inhibition of proliferation is plotted as the percent of control. The mean 
IC50’s for each drug in both cell lines, and the fold difference in sensitivity between lines, is tabulated. Loss of RAD51D increased sensitivity 
to both drugs. Data represent the mean of two independent experiments, error bars represent SEM. B) HRR compromised cells are unable 
to completely repair vosaroxin- and doxorubicin-induced DNA damage. RAD51D1 and RAD51D1.3 cells were treated for 6 hr with 0.11 
μM vosaroxin, 1 µM doxorubicin, or with DMSO control, followed by washout and temporal evaluation of recovery from DNA damage, via 
quantification of γH2AX foci. DNA damage was evaluated upon compound removal (at 6 hr) and 16, 24 and 40 hr after washout. The graphs 
show the percent of cells at each time point with >5 γH2AX foci. Repair of DNA damage was compromised following treatment with each 
drug. Data represent the mean of 2 independent experiments, error bars represent SEM. Representative images are shown for each cell line at 
the time of compound removal and 24 hr following washout. 
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BRCA2 deficiency sensitizes cells to vosaroxin 
and doxorubicin 
The role of BRCA2 in HRR, and the established 
synthetic lethality of molecules targeting DNA damage 
and repair in the BRCA2 mutant background [36-38], 
prompted the analysis of vosaroxin sensitivity in CHO cell 
lines mutant (V-C8) and competent for BRCA2 (V-C8B2, 
BRCA2 reconsitituted) [39]. BRCA2 mutation sensitized 
cells to inhibition of proliferation by both vosaroxin (5.1-
fold) and, in keeping with data reported by Spencer et al 
[23], doxorubicin (3.8 fold) (Figure 6A). Further, in the 
U20S human sarcoma cell line, siRNA knockdown of 
BRCA2 induced a 4.6-fold sensitization to colony growth 
inhibition by both vosaroxin and doxorubicin (Figure 
6B). Thus the cytotoxicity of both agents is influenced 
to a comparable extent by the functionality of the HRR 
pathway, despite differential induction of HRR-mediated 
recombination events during DNA synthesis.
DIscUssION
The studies reported here provide molecular detail 
of the mechanism of action of vosaroxin, the first of a new 
class of antineoplastic agents, the anticancer quinolone 
derivatives. These data establish that vosaroxin-induced 
DNA DSB are preferential for replicating cells. Consistent 
with the interdependence of DNA repair mechanisms, 
DNA replication and cell cycle checkpoints [40, 41], the 
mechanisms invoked to repair these DSB differ with cell 
cycle phase. Further, several points of differentiation from 
the classic topoisomerase II poison, doxorubicin, were 
identified, largely occurring during the S phase of the cell 
cycle.
The relative induction of damage induced during G2 
/ M > S >> G1 is consistent with previous reports that 
Figure 6: brcA2 loss sensitizes cells to vosaroxin and doxorubicin. A) Cells expressing truncated BRCA2 are sensitized to 
vosaroxin more than doxorubicin. VC8 (mutant BRCA2) and VC8-B2 (restored BRCA2) cells were treated for 4 hr with a dose-titration of 
vosaroxin, doxorubicin, or with DMSO control. Inhibition of proliferation was evaluated following 5 days incubation and is represented as 
percent of DMSO control. Graphs represent the mean of 2 independent experiments and error bars represent SEM. The shift in IC50 between 
cell lines is shown for each compound. B) BRCA2 knockdown sensitizes cells equally to vosaroxin and doxorubicin. siRNA knockdown of 
BRCA2 was performed in U20S human sarcoma cells, followed by treatment with a dose-titration of vosaroxin or doxorubicin, or with DMSO 
control. Colony growth inhibition was evaluated following 14 days incubation and is graphed relative to DMSO control. Error bars represent 
SEM. The efficiency of knockdown at 24 and 48 hr post transfection, with BRCA2 siRNA or transfection agent alone (-) is shown. The shift in 
IC50 between conditions is shown for each compound.
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analyze the cell cycle phase of DNA DSB induction by 
topoisomerase II targeting agents [42], and with the peak 
in expression of topoisomerase IIα at the G2 phase of the 
cell cycle [7, 12, 13, 15]. Both vosaroxin and doxorubicin 
induced DSB during G2 / M, as established by detectable 
DNA fragmentation and consequent HRR-mediated long 
tract recombination. Consistent with these observations, 
the majority of vosaroxin and doxorubicin-induced 
cytotoxicity occurred independent of S phase, indicating 
that the DSB induced during G2 / M are the principal 
cause of cytotoxicity. 
Points of contrast between vosaroxin and doxorubicin 
were identified in their S phase-induced DNA damage 
and associated DNA damage responses. Allthough 
vosaroxin’s S phase-induced DNA damage triggered the 
HRR response, as detected by RAD51 focus formation, 
Figure 7: Model for induction of differential, cell cycle phase specific DNA damage and HRR processes following exposure 
to vosaroxin or doxorubicin. DNA in G2 / M phase is shown on the left, with the replication fork advancing during S phase to the right. 
Points of homologous recombination are depicted by X, with the region exchanged depicted by the horizontal arrow. These regions also 
represent potential DNA fragments in the absence of DNA repair. A) Vosaroxin-induced DNA damage is depicted in the upper model, where the 
replication fork is stalled due to topologic stress in DNA, resulting in a prolonged S phase and the induction of RAD51 foci. Replication fork 
collapse is either below detectable levels or is absent, evidenced by undetectable DNA fragmentation or HRR-mediated long tract recombination 
during S phase. The toxicity of S phase induced lesions is low. In G2 / M phase, DNA DSB induction is maximal, inducing detectable DNA 
fragmentation, HRR-mediated long tract recombination and maximal toxicity. B) Doxorubicin-induced DNA damage is depicted in the lower 
model, where in addition to cleavable complexes base mutations, DNA cross-linking and DNA adducts are also generated. The advancing 
replication fork encounters torsional stress in the DNA and RAD51 foci are induced. A proportion of active replication forks collide with DNA 
lesions (shown here as a DNA adduct), inducing DNA fragmentation (represented by the horizontal arrows) and long tract recombination, 
indicating replication fork collapse. Sites for additional potential fork collapse are shown by the X, in regions of doxorubicin-DNA cross links 
and adducts. Fewer DNA DSB are formed in S phase than in G2 / M and cytotoxicity of the lesions is lower. In G2 / M phase, DNA DSB 
induction is maximal, resulting in increased DNA fragmentation, HRR-mediated long tract recombination and maximal toxicity. Because of 
the increased number and / or diversity of DNA interactions, DNA DSB induction and fragmentation is greater than that induced by vosaroxin, 
so generating an increased number of smaller (1.6 – 0.2 Mbp) fragments. This is represented by the increased number of, and smaller size of, 
the horizontal arrows.
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A
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HRR-mediated long tract recombination
Regions of potential DNA fragmentation
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ROS-induced base mutation
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B
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this DNA damage was not associated with detectable 
DSBs or recombination. This indicates that replication 
fork collapse is absent in vosaroxin-treated cells, or 
occurs below the level of detection. Vosaroxin did induce 
a dose-dependent S phase delay, suggesting that cleavable 
complexes form a replication fork barrier, consistent with 
previously reported data [43]. Contrasting with vosaroxin, 
a greater number of DNA fragments (0.2 – 1.6 Mbp) were 
induced by doxorubicin, which also caused replication 
fork collapse as evidenced by detectable levels of DNA 
fragmentation and long tract recombination during S 
phase. 
These data are summarized in a model in which 
vosaroxin induces two major forms of toxic DNA lesion 
that are repaired by HRR, and are generated during 
different phases of the cell cycle (Figure 7A). During 
DNA synthesis in vosaroxin treated cells, the replication 
fork may encounter torsional stress due to cleavage 
complexes in proximity to the sites of DNA replication. 
The HRR response is activated and localized to the 
region of the replication fork which stalls, slowing DNA 
synthesis. The advancing fork does not collide with the 
lesion or collapse, thus DNA fragmentation and long 
tract recombination are undetectable and the toxicity of 
these lesions is low. During G2 / M, where the cell is 
actively dividing and when topoisomerase IIα expression 
is elevated, vosaroxin induces an increased number of 
topoisomerase II-mediated DSB and detectable DNA 
fragmentation, maximizing cytotoxicity during this phase. 
Long tract repair via HR contributes to cellular recovery 
from the damage. 
Replication forks collapse when they collide with 
regions of damaged DNA, and when DNA repair processes 
are unable to stabilize or re-start stalled or blocked forks 
[40, 44]. The combined effects of disparity in both number 
and mode of molecular interactions with DNA, as a 
consequence of their contrasting chemical structures [1], 
is a plausible explanation for the differences in the DNA 
damage and HRR induced by vosaroxin and doxorubicin, 
and is represented as a model in Figure 7B. Although both 
drugs intercalate DNA and poison topoisomerase II, the 
anthracyclines induce DNA damage through additional, 
non topoisomerase II-mediated mechanisms [20, 22], 
including the induction of ROS. Anthracycline-induced 
ROS generate mutagenic base modifications [19, 45] 
and drive the formation of additional bulky lesions in 
the form of DNA adducts and crosslinks [21-26], lesions 
which cause replication fork stall [40, 46] and collapse 
[47]. HR plays a role in the repair of these forms of 
damage [23, 47, 48], and the DSB caused by interstrand 
crosslinks are in particular associated with the S phase of 
the cell cycle [49]. Following doxorubicin treatment these 
diverse drug / DNA interactions may induce enough S 
phase DNA damage and / or generate a particularly toxic 
form of lesion(s), to drive the observed replication fork 
collapse. The contributions of the different anthracycline- 
DNA interactions to cytotoxicity of the drugs are as 
yet unresolved [20, 22]. In contrast vosaroxin produces 
minimal ROS [1] and the generation of ROS or DNA 
alkylation are not characteristics of the quinolone core. 
Thus vosaroxin may produce fewer bulky lesions in S 
phase, predominantly in the form of topoisomerase II 
cleavage complexes, a consequence of which is minimal 
or absent replication fork collapse. The overall reduction 
in DNA fragmentation, relative to doxorubicin, may also 
be attributable to these contrasts in molecular reactivity. 
Despite these molecular mechanistic differences, 
vosaroxin induced S phase dependent toxicity that was 
comparable with doxorubicin. This may be due to a 
requirement for cells to pass through S phase and reach 
G2 / M phases where vosaroxin activity is maximal. 
The increased vosaroxin sensitivity of HRR mutant 
cells forms the basis of a clinically testable hypothesis, 
exploiting synthetic lethality to target identifiable 
subpopulations which may be particularly sensitive to 
the drug. These include tumors harboring mutations in 
BRCA1 and 2, which impair HRR and increase sensitivity 
to drugs that target DNA repair pathways [36-38, 50]. 
Indications harboring such mutations include breast 
(particularly triple negative breast cancer), prostate and 
ovarian cancers [50-53]. 
Collectively, the data reported here establish a 
cell cycle phase specific pattern of vosaroxin-induced 
DNA damage and fragmentation, and the reflection of 
these in the induction of critical, phase-specific HRR 
response processes. Points of contrast between vosaroxin 
and doxorubicin in the extent and timing of DNA 
fragmentation, and the phase-specific HRR processes that 
are induced, highlight molecular mechanistic divergence 
between these structurally unrelated topoisomaerase II 
poisons. These mechanistic observations are critical to 
the generation of clinically testable hypotheses that drive 
rational drug development. 
MAtErIALs AND MEtHODs
cells and cell culture
MO59K, A549 and U20S cell lines were obtained 
from American Type Culture Collection. RAD51D1 and 
RAD51D1.3 Chinese Hamster Ovarian (CHO) matched 
clones were the kind gift of Dr Lawrence Thompson, 
Lawrence Livermore Research Laboratories, CA. The 
CHO cell lines SPD8, VC8 and VC8B2 have been 
previously described [38, 54].
A549, MO59K and RAD51D matched clones were 
cultured and maintained at 37ºC and 5% CO2 atmosphere 
in RPMI-1640 media supplemented with 10% fetal bovine 
serum (Cellgro). U20S and VC8 cell lines were cultured 
and maintained in Dulbecco’s Modified Eagle’s Medium 
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(DMEM), with the addition of 9% fetal calf serum and 
penicillin-streptomycin (90 U/mL) at 37ºC and 5% CO2 
atmosphere. VC8-B2 cells were cultured in DMEM as 
above, with the addition of G418 (Sigma Aldrich) to 100 
µg/mL. SPD8 cells were cultured in DMEM containing 
9% fetal calf serum, penicillin-streptomycin and 
6-Thioguanine (6TG, 5 µg/mL; Sigma Aldrich) in order 
to kill cells that undergo spontaneous reversion.
The SPD8 cell line contains an inactivating partial 
duplication of the hprt gene that serves as an endogenous 
readout for HRR; a functional gene is regenerated through 
reversion mediated by long tract HRR [54]. These cells 
were therefore used to evaluate the induction of HR-
mediated reversion following treatment with compound. 
The same cells were used for compound-induced 
DNA fragmentation, cytotoxicity and HRR activation 
experiments, allowing for the evaluation of the HRR 
response in a consistent cellular background. 
The CHO AA8 RAD51D mutant cell line (clone 
51D1) harbors a genetic knockout of RAD51D and shows 
increased sensitivity to DNA DSB-inducing agents, 
while the matched line (clone 51D1.3) is reconstituted 
for RAD51D expression [35]. These cells were used to 
examine the drug sensitivity of HRR compromised cells.
The VC8 cell line has a truncating mutation in the 
brca2 gene and VC8-B2 is this cell line complemented 
with the human chromosome 13 (containing the brca2 
gene) [39]. These cells were used to evaluate the role 
of BRCA2 in recovery from compound-induced DNA 
damage.
reagents
Aphidicolin (Sigma Aldrich), doxorubicin (Sigma 
Aldrich) and vosaroxin (Sunesis Pharmaceuticals) were 
dissolved in dimethylsulfoxide (DMSO) to a maximal 
final DMSO concentration of 0.2%. 
Immunofluorescence analyses
Detection of γH2AX and pericentrin foci in MO59K 
cells:
MO59K glioma cells are large, highly adherent 
and thus amenable to centrosome staining and analysis 
via immunofluorescence. Cells were seeded overnight at 
10,000 / well in 96-well plates, followed by 6 hr treatment 
with compound. At 6 hr cells were fixed, permeabilized 
and stained for γH2AX and pericentrin as follows. 
Cells were washed in PBS and fixed for 10 mins with 
0.2% paraformaldehyde in PBS. Paraformaldehyde was 
removed and the cells permeabilized for 5 mins with 0.5% 
TritonX-100, then washed with PBS and fixed with 2% 
paraformaldehyde in PBS for 10 mins. Following a PBS 
wash, cells were blocked for 1 hr with 5% BSA in PBS 
and incubated overnight at 4oC with primary antibodies 
(see below). Cells were washed with PBS and incubated 
in the dark for 1 hr at room temperature in secondary 
antibodies (see below). Cells were then washed in PBS 
and nuclei stained by adding 1 ug/ml Hoechst 33342 in 
PBS to each of the wells. The cells were analyzed using 
an ArrayScan high content screening device. Nuclei were 
identified as objects based on the Hoechst 33342 stain. 
γH2AX staining: γH2AX was detected using mouse 
anti- γH2AX (Upstate 05-636) diluted 1:500 in 1% BSA 
in PBS. Secondary antibody, AlexaFluor 594-conjugated 
goat anti-mouse (Invitrogen A31623), was diluted 1:300 
in 1% BSA in PBS. For MO59K cells, the mean γH2AX 
intensity was measured for each nucleus. For RAD51D1 
and D1.3 cells γH2AX foci were counted within each 
nucleus, and a cell was considered to be positive for 
γH2AX if the nucleus contained >5 foci. 
Pericentrin staining: Pericentrin was detected using 
rabbit anti-pericentrin (Abcam; ab4448) diluted to 1:1000 
in 1% BSA in PBS. Secondary antibody, AlexaFluor 
488-conjugated anti-rabbit IgG secondary antibody 
(Invitrogen, A11008), was diluted 1:1000 in 1% BSA in 
PBS. Cells were assigned to cell cycle phases as follows: 
small single nucleus, G1; larger, more diffuse nucleus, late 
S / G2; two nuclei, M.
Detection of γH2AX foci inRAD51D CHO cells:
RAD51D1 and RAD51D1.3 cells were seeded 
overnight at 10,000 / well in 96-well plates, followed by 6 
hr treatment with compound or DMSO control diluted in 
growth media. Each treatment was performed in duplicate. 
Cells were then washed with fresh media and grown in 
the absence of compound. At washout and 16, 24, and 40 
hr post washout the cells were fixed, permeabilized, and 
stained for nuclei and γH2AX as described above. 
Detection of RAD51 foci in SPD8 cells:
Cells were seeded overnight at 8,000 / well in 96-
well plates, followed by 4 hr treatment with vosaroxin 
or doxorubicin +/- aphidicolin, aphidicolin alone or with 
DMSO control diluted in growth media. Cells were fixed 
for 20 min in 4% paraformaldehyde in PBS-T (PBS + 0.1% 
Triton X-100), washed in PBS, permeabilized with PBS + 
0.3% Triton X-100 and blocked for 40 mins with 3% BSA 
in PBS. Cells were incubated overnight at 4 oC with rabbit 
anti-RAD51 (Santa Cruz Biotechnology, H-92) diluted 
1:1000 in 3% BSA in PBS. Following PBS wash cells 
were labeled for 1 hr, at room temperature in the dark, 
with alexa 488-conjugated goat anti-rabbit (Invitrogen, 
A31629) diluted 1:500 in 3% BSA. After PBS wash, cells 
were stained for 5 mins at room temperature with 50 µL 
DAPI (1 µg/mL), washed and analyzed using an INCell 
Analyzer 1000 (GE Healthcare). Images were analysed 
using the INCell Analyzer 1000 Workstation software (GE 
Healthcare), counting at least 300 nuclei per treatment 
condition. Each treatment was performed in sextuplicte or 
septuplicate. A cell was considered as positive for RAD51 
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foci if it contained >9 foci. 
Pulsed-Field Gel Electrophoresis (PFGE)
SPD8 cells were seeded overnight at 2x106 /75 
cm2 flasks, followed by 4 hr treatment with vosaroxin or 
doxorubicin +/- aphidicolin. Cells were washed with PBS 
before being melted into agarose inserts (1x106 cells/70 
µL 1% InCert Agarose, BMA), cooled at 4 oC and placed 
in sarcosyl solution (1% N-laurylsarcosyl, 1 mg/mL 
proteinase K, 0.5 M EDTA pH 8.0) at 50°C for 48 hours. 
Control inserts were irradiated with 50 Gy γ-irradiation 
in a Cs137 chamber (1.9 Gy/min) prior to incubation in 
sarcosyl solution. Inserts were rinsed 4 times for 2 hrs 
in TE and loaded into the wells of a 1% Chromosomal 
grade agarose gel (BioRad). Separation was performed 
on a CHEF DR III (BioRad; 120°, field switch 60-240 
sec, 4 V/cm) for 24 hr at 14 oC. The gel was stained with 
ethidium bromide for 5 hours and subsequently analyzed 
by scanning fluorescence reader (Molecular Imager FX, 
Biorad) using Quantative One software.
colony growth inhibition
SPD8 cells were seeded at 1.5 x 106/75 cm2 flask and 
incubated 24 hr prior to 4 hr treatment with vosaroxin, 
doxorubicin or DMSO control +/- aphidicolin. Compound 
was washed out and cells incubated for 48 hrs, then plated 
in duplicate in 10 cm dishes at 500 cells / dish (or seeded 
for reversion assay analysis as described below). After 7 
day incubation the plates were harvested and the colonies 
fixed and stained using methylene blue in methanol (4 
g/L). Colonies containing more than 50 cells were counted.
reversion assay
SPD8 cells were seeded and treated as described 
above for analysis of colony growth inhibition, thus 
cytotoxicity and reversion are established from the 
same population of treated cells. For reversion analysis, 
following drug exposure, washout and recovery, cells were 
seeded in triplicates at 3 x 105 cells / dish in the presence 
of HAsT (50 µM hypoxanthine,10 µM L-azaserine, 5 
µM thymidine) to select for revertants to wild type hprt, 
and incubated for 10 days. Plates were harvested and 
the colonies fixed and stained using methylene blue in 
methanol (4 g/L). Colonies containing more than 50 cells 
were counted.
Measurement of rAD51D1 and rAD51D1.3 
proliferation by Mtt
RAD51D1 and RAD51D1.3 cells were plated and 
grown overnight in 96-well plates at 2000 cells / well and 
treated (in duplicates) with a dose-titration of vosaroxin, 
or with DMSO control, for 72 hr. After treatment, MTT 
reagent (5 mg/mL, Sigma-Aldrich) was added directly to 
the media and incubated at 37°C/5% CO2 for 2 h. MTT 
lysis buffer was added and cells were incubated at 37°C/5% 
CO2 overnight. Samples were analyzed by measuring the 
light absorbance at 595 nm using a SpectraMax plate 
reader (Molecular Devices). Values obtained for treatment 
samples were normalized to control samples. 
Measurement of Vc8 and Vc8-b2 proliferation 
by resazurin
VC8 and VC8-B2 cells were plated and grown 
overnight in 96-well plates at 4000 cells/well and treated 
for 4 hr (in duplicate) with serial dilution of drug or with 
vehicle control. Following PBS rinse cells were incubated 
for 5 days before staining with resazurin (10µg/mL 
DMEM). Fluorescence was measured using the Envision 
plate reader (Ex530nm/Em590nm, Perkin Elmer) and 
growth inhibition plotted as percentage fluorescence 
compared to untreated cells. 
sirNA knockdown and U20s colony growth 
inhibition 
U20S human sarcoma cells were seeded in 6 well 
plates, 2 x 105 / well, and incubated overnight. Cells 
were transfected with 100 pmol siBRCA2 (siGenome 
SMARTpool, 5’-GAAACGGACUUGCUAUUUA-3’, 
5 ’ - G U A A A G A A A U G C A G A A U U C - 3 ’ , 
5 ’ - G G U A U C A G A U G C U U C A U U A - 3 ’ , 
5’-GAAGAAUGCAGGUUUAAUA-3’ Dharmacon) 
mixed with 2 µL DharmaFect 1 (Dharmacon), or with 
transfection reagent alone, in a total volume of 2 mL 
antibiotic free media. Following 24 hr incubation cells 
were trypsinized, counted and seeded into 10 cm plates at 
500 or 1000 cells / plate. After 4 hr incubation cells were 
treated with a dose-titration of vosaroxin or doxorubicin 
and incubated for 14 days. Colonies were fixed and stained 
using methylene blue as described above. 
Western blot
Cell lysates were separated on a 3-8% Tris-Acetate 
gel, transferred to nitrocellulose membrane, the membrane 
cut to allow dual analysis of target and control antigen 
and incubated overnight at 4oC in either mouse anti-PARP 
(Santa Cruz Biotechnology, clone PARP-1 (F-2) or mouse 
anti-BRCA2 (Calbiochem, OP95) antibody, diluted 
1:500 in 5% milk-TBST. Membranes were washed in 
TBST, incubated for 1 hr at room temperature with HRP-
conjugated anti-mouse antibody (Millipore, AP501P), 
washed and developed using chemiluminescence (Roche).
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